A subset analysis of a phase II trial evaluating the use of DFMO as maintenance therapy for high‐risk neuroblastoma

Neuroblastoma is a sympathetic nervous system tumor, primarily presenting in children under 6 years of age. The long‐term prognosis for patients with high‐risk neuroblastoma (HRNB) remains poor despite aggressive multimodal therapy. This report provides an update to a phase II trial evaluating DFMO...

Descripción completa

Detalles Bibliográficos
Autores principales: Lewis, Elizabeth C., Kraveka, Jacqueline M., Ferguson, William, Eslin, Don, Brown, Valerie I., Bergendahl, Genevieve, Roberts, William, Wada, Randal K., Oesterheld, Javier, Mitchell, Deanna, Foley, Jessica, Zage, Peter, Rawwas, Jawhar, Rich, Maria, Lorenzi, Elizabeth, Broglio, Kristine, Berry, Donald, Saulnier Sholler, Giselle L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Cancer Therapy and Prevention
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7586843/
https://www.ncbi.nlm.nih.gov/pubmed/32391579
http://dx.doi.org/10.1002/ijc.33044

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7586843/
https://www.ncbi.nlm.nih.gov/pubmed/32391579
http://dx.doi.org/10.1002/ijc.33044

Ejemplares similares